Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Compassionate access anti-tumour necrosis factor-α therapy for ulcerative colitis in Australia: the benefits to patients.
Costello SP, Ghaly S, Beswick L, Pudipeddi A, Agarwal A, Sechi A, O'Connor S, Connor SJ, Sparrow MP, Bampton P, Walsh AJ, Andrews JM; Australian Inflammatory Bowel Disease Association (AIBDA). Costello SP, et al. Among authors: pudipeddi a. Intern Med J. 2015 Jun;45(6):659-66. doi: 10.1111/imj.12732. Intern Med J. 2015. PMID: 25732268
Conflict of interest: real and perceived--a more mature consideration is needed.
Andrews JM, Costello SP, Agarwal AK, Bampton P, Beswick L, Connor S, Ghaly S, O'Connor S, Pudipeddi A, Sechi A, Sparrow M, Walsh AJ. Andrews JM, et al. Among authors: pudipeddi a. Intern Med J. 2016 Mar;46(3):377-9. doi: 10.1111/imj.12989. Intern Med J. 2016. PMID: 26968604 No abstract available.
Safety of drugs used for the treatment of Crohn's disease.
Pudipeddi A, Kariyawasam V, Haifer C, Baraty B, Paramsothy S, Leong RW. Pudipeddi A, et al. Expert Opin Drug Saf. 2019 May;18(5):357-367. doi: 10.1080/14740338.2019.1612874. Epub 2019 May 6. Expert Opin Drug Saf. 2019. PMID: 31026401 Review.
High prevalence of Crohn disease and ulcerative colitis among older people in Sydney.
Pudipeddi A, Liu J, Kariyawasam V, Borody TJ, Cowlishaw JL, McDonald C, Katelaris P, Chapman G, Corte C, Lemberg DA, Lee CH, Keshava A, Napoli J, Clancy R, Chan W, Paramsothy S, Leong R. Pudipeddi A, et al. Med J Aust. 2021 May;214(8):365-370. doi: 10.5694/mja2.50910. Epub 2021 Jan 27. Med J Aust. 2021. PMID: 33502004
Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
Pudipeddi A, Ko Y, Paramsothy S, Leong RW. Pudipeddi A, et al. Therap Adv Gastroenterol. 2022 Mar 8;15:17562848221080793. doi: 10.1177/17562848221080793. eCollection 2022. Therap Adv Gastroenterol. 2022. PMID: 35282607 Free PMC article.
35 results